Incyte Corporation $INCY Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in shares of Incyte Corporation (NASDAQ:INCY - Free Report) by 11.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 210,097 shares of the biopharmaceutical company's stock after purchasing an additional 21,735 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.11% of Incyte worth $20,719,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. AustralianSuper Pty Ltd bought a new position in shares of Incyte during the 3rd quarter valued at about $18,085,000. Rakuten Investment Management Inc. bought a new position in shares of Incyte during the 3rd quarter valued at about $14,646,000. LBP AM SA boosted its position in shares of Incyte by 33.6% during the 3rd quarter. LBP AM SA now owns 238,705 shares of the biopharmaceutical company's stock valued at $20,245,000 after purchasing an additional 59,974 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Incyte by 38.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 387,605 shares of the biopharmaceutical company's stock valued at $32,873,000 after purchasing an additional 108,645 shares in the last quarter. Finally, Nordea Investment Management AB boosted its position in shares of Incyte by 941.8% during the 4th quarter. Nordea Investment Management AB now owns 322,223 shares of the biopharmaceutical company's stock valued at $31,874,000 after purchasing an additional 291,293 shares in the last quarter. Institutional investors own 96.97% of the company's stock.

Insider Activity at Incyte

In related news, insider Pablo J. Cagnoni sold 18,667 shares of the firm's stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $96.50, for a total transaction of $1,801,365.50. Following the completion of the sale, the insider directly owned 262,692 shares in the company, valued at approximately $25,349,778. This trade represents a 6.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 17.80% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on INCY. HC Wainwright restated a "buy" rating and set a $135.00 price objective on shares of Incyte in a research report on Wednesday, April 15th. UBS Group decreased their target price on shares of Incyte from $104.00 to $94.00 and set a "neutral" rating for the company in a report on Wednesday, March 25th. The Goldman Sachs Group reissued a "neutral" rating and issued a $90.00 target price on shares of Incyte in a research report on Thursday, January 8th. Barclays reissued an "overweight" rating on shares of Incyte in a research report on Tuesday, March 24th. Finally, Jefferies Financial Group downgraded shares of Incyte from a "buy" rating to a "hold" rating and dropped their target price for the stock from $120.00 to $94.00 in a research report on Monday, March 16th. Ten research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $104.89.

Incyte Stock Performance

Incyte stock opened at $94.65 on Friday. The firm's 50 day simple moving average is $96.09 and its 200-day simple moving average is $98.41. The company has a market cap of $18.84 billion, a P/E ratio of 14.77, a price-to-earnings-growth ratio of 0.76 and a beta of 0.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 3.25. Incyte Corporation has a fifty-two week low of $57.77 and a fifty-two week high of $112.29.

Incyte (NASDAQ:INCY - Get Free Report) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing the consensus estimate of $1.96 by ($0.16). The firm had revenue of $1.51 billion during the quarter, compared to analysts' expectations of $1.35 billion. Incyte had a return on equity of 26.34% and a net margin of 25.03%.The business's revenue was up 27.8% on a year-over-year basis. During the same period last year, the business earned $1.43 earnings per share. As a group, equities research analysts predict that Incyte Corporation will post 6.52 EPS for the current year.

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company's research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company's flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.